EVISA Glossary on | Contact EVISA | Sitemap | Home   
Search
 Advanced search
The establishment of EVISA is funded by the EU through the Fifth Framework Programme (G7RT- CT- 2002- 05112).


Supporters of EVISA includes:
Chemocare: Cisplatin

Link http://chemocare.com/chemotherapy/drug-info/cispla
tin.aspx
Elements Platinum
Species Complex
Topic Information - Pharmacy/Pharmacology
Owner Company
Location ----
Language English
Description
Cisplatin is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug.  Cisplatin is classified as an "alkylating agent."   (For more detail, see "How Cisplatin Works" section below).





Events
See the complete list of deadlines!
AIRMON 2025: 11th International Symposium on Modern Principles of Air Monitoring and Biomonitoring
15.06.2025
Loen, Norway
ISABC 17: 17th International Symposium on Applied Bioinorganic Chemistry
15.06.2025
Uppsala Sweden
HPLC 2025: 54th International Symposium on High Performance Liquid Phase Separations and Related Techniques
15.06.2025
Bruges, Belgium
... more Events
News
What's new on EVISA's web site ?
Identification of cadmium-chelating compounds in plant-based foods using SEC-ICP‑MS/MS and SEC-QTOF-MS
A new human hair certified reference material for total mercury, methylmercury, and trace element analyses
Speciation analysis in routine applications
Speciation Analysis – A Key Focus in Analytical Chemistry
... more News




Imprint     Disclaimer

© 2003 - 2025 by European Virtual Institute for Speciation Analysis ( EVISA )